Oragenics (OGEN) Cash from Financing Activities (2010 - 2026)
Oragenics' (OGEN) quarterly Cash from Financing Activities came in at -$92004.0 in Q1 2026, down 101.97% YoY from $4.7 million in Q1 2025, and up 45.44% on a QoQ basis from -$168628.0 in Q4 2025.
Oragenics (OGEN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Cash from Financing Activities data on file, last reported at -$92004.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 101.97% year-over-year to -$92004.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (up 33.65% YoY) and the FY2025 annual result came in at $16.8 million, up 180.68% from the prior year.
- Cash from Financing Activities climbed to -$92004.0 in Q1 2026, from -$168628.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $12.4 million in Q3 2025 to a low of -$260856.0 in Q4 2024.
- A 5-year average of $1.3 million and a median of -$103505.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 372.39% — and 2024, when it soared 1134.58%.
- Tracing OGEN's Cash from Financing Activities over 5 years: stood at -$87995.0 in 2022, then plunged by 105.24% to -$180599.0 in 2023, then slumped by 44.44% to -$260856.0 in 2024, then jumped by 35.36% to -$168628.0 in 2025, then surged by 45.44% to -$92004.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$92004.0 (Q1 2026), -$168628.0 (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | -56,134.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56,134.00 |
| Jun 30, 2026 | -56,134.00 |
| Mar 31, 2026 | -92,004.00 |
| Mar 31, 2026 | -92,004.00 |
| Dec 31, 2025 | -168,628.00 |
| Dec 31, 2025 | -168,628.00 |
| Sep 30, 2025 | 12.41 Mn |
| Sep 30, 2025 | 12.41 Mn |
| Jun 30, 2025 | -132,963.00 |
| Jun 30, 2025 | -132,963.00 |
| Mar 31, 2025 | 4.67 Mn |
| Mar 31, 2025 | 4.67 Mn |
| Dec 31, 2024 | -260,856.00 |
| Dec 31, 2024 | -260,856.00 |
| Sep 30, 2024 | 3.77 Mn |
| Sep 30, 2024 | 3.77 Mn |
| Jun 30, 2024 | 821,161.00 |
| Jun 30, 2024 | 821,161.00 |
| Mar 31, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.65 Mn |